This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
by Zacks Equity Research
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
by Zacks Equity Research
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
by Zacks Equity Research
REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
by Zacks Equity Research
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
by Zacks Equity Research
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
by Zacks Equity Research
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
by Zacks Equity Research
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
by Zacks Equity Research
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
by Zacks Equity Research
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
by Zacks Equity Research
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
by Zacks Equity Research
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.